| Literature DB >> 15619406 |
Ricardo A Costa1, Alexandra J Lansky, Gary S Mintz, Roxana Mehran, Yoshihiro Tsuchiya, Manuela Negoita, Yael Gilutz, Eugenia Nikolsky, Martin Fahy, Ramona Pop, Ecaterina Cristea, Stephane Carlier, George Dangas, Gregg W Stone, Martin B Leon, Ralf Müller, George Techen, Eberhard Grube.
Abstract
The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 +/- 0.22 vs 0.85 +/- 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 +/- 12.3% vs 37.0 +/- 15.8%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15619406 DOI： 10.1016/j.amjcard.2004.08.074
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778